FDA’s Progress On Biomarkers: Two Steps Forward, One Step Back?
Executive Summary
FDA is moving ahead with its biomarker validation efforts with the establishment of a consortium with the Pharmaceutical Research & Manufacturers of America and NIH, but the agency has halted an internal biomarker survey in favor of a broader inventory of endpoints
You may also be interested in...
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
The Institute of Medicine urges the agency to create a publicly available document setting forth benefits and risks of drugs, with periodic updates, but FDA says it has no extra resources to handle such an effort.
Critical Path Consortium To Allow Patents But Preserve Access For Partners
The Predictive Safety Testing Consortium will allow companies to patent safety testing methodologies developed through the collaboration, but firms will be required to grant access to other members
Critical Path Consortium To Allow Patents But Preserve Access For Partners
The Predictive Safety Testing Consortium will allow companies to patent safety testing methodologies developed through the collaboration, but firms will be required to grant access to other members